Login to Your Account



Altor Launches Clinical Program for Longer and Stronger IL-15

By Catherine Shaffer
Staff Writer

Thursday, August 15, 2013
Interleukin-15 (IL-15) is considered to be a critical factor in development, proliferation and activation of the cellular immune response, and as such a promising cancer immunotherapeutic agent that is being tested in clinical studies by the National Cancer Institute and the National Institutes of Health. However, IL-15 is limited by a very short half-life in the body.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription